Search

Your search keyword '"Merle, Philippe"' showing total 844 results
Start Over Author "Merle, Philippe"
844 results on '"Merle, Philippe"'

1. Predictive and Prognostic Potential of Liver Function Assessment in Patients with Advanced Hepatocellular Carcinoma: A Systematic Literature Review.

Author

Vogel, Arndt, Johnson, Philip, Merle, Philippe, Yau, Thomas, Kudo, Masatoshi, Meyer, Tim, Rimassa, Lorenza, and Kelley, Robin

Subjects
Advanced hepatocellular carcinoma, Albumin bilirubin, Child-Pugh, Liver function, Predictive potential, Prognostic potential
Abstract

INTRODUCTION: We conducted a systematic literature review to assess the utility of liver function assessments for predicting disease prognosis and response to systemic anticancer therapy in patients with advanced hepatocellular carcinoma (aHCC). METHODS: This was a PRISMA-standard review and was registered with PROSPERO (CRD42021244588). MEDLINE and Embase were systematically searched (March 24, 2021) to identify publications reporting the efficacy and/or safety of systemic anticancer therapy (vs. any/no comparator) in liver-function-defined subgroups in phase 2 or 3 aHCC trials. Screening was completed by a single reviewer, with uncertainties resolved by a second reviewer and/or the authors. English-language full-text articles and congress abstracts were eligible for inclusion. Included publications were described and assessed for risk of bias using the GRADE methodology. RESULTS: Twenty (of 2,579) screened publications were eligible; seven categorized liver function using the albumin-bilirubin system, nine using the Child-Pugh system, four using both. GRADE assessment classified ten, nine, and one publication(s) as reporting moderate-quality, low-quality, and very-low-quality evidence, respectively. Analyses of cross-trial trends of within-exposure arm analyses (active and control) reported a positive relationship between baseline liver function and overall survival and progression-free survival, supporting liver function as a prognostic marker in aHCC. There were also signals for a modest relationship between more preserved baseline liver function and extent of systemic treatment benefit, and with more preserved liver function and lower incidence of safety events. CONCLUSION: This review supports liver function as a prognostic variable in aHCC and highlights the value of a priori stratification of patients by baseline liver function in aHCC trials. The predictive value of liver function warrants further study. Findings were limited by the quality of available data.

Published
2023

2. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study

Author

Yau, Thomas, Kaseb, Ahmed, Cheng, Ann-Lii, Qin, Shukui, Zhu, Andrew X, Chan, Stephen L, Melkadze, Tamar, Sukeepaisarnjaroen, Wattana, Breder, Valery, Verset, Gontran, Gane, Edward, Borbath, Ivan, Rangel, Jose David Gomez, Ryoo, Baek-Yeol, Makharadze, Tamta, Merle, Philippe, Benzaghou, Fawzi, Milwee, Steven, Wang, Zhong, Curran, Dominic, Kelley, Robin Kate, and Rimassa, Lorenza

Published
2024
Full Text
View/download PDF

3. Experimental Campaign for the Ductility Assessment for Reinforced Concrete Walls and Slabs of Nuclear Power Plants

Author

Huguet, Miquel, Bisch, Philippe, Bou-Said, Elias, Erlicher, Silvano, Gallitre, Etienne, Mertz, Pierre-Yves, Courtois, Alexis, Merle, Philippe, Meuzard, Rémi, di Prisco, Marco, Series Editor, Chen, Sheng-Hong, Series Editor, Vayas, Ioannis, Series Editor, Kumar Shukla, Sanjay, Series Editor, Sharma, Anuj, Series Editor, Kumar, Nagesh, Series Editor, Wang, Chien Ming, Series Editor, Ilki, Alper, editor, Çavunt, Derya, editor, and Çavunt, Yavuz Selim, editor

Published
2023
Full Text
View/download PDF

5. Model-Based Cloud Resource Management with TOSCA and OCCI

Author

Challita, Stéphanie, Korte, Fabian, Erbel, Johannes, Zalila, Faiez, Grabowski, Jens, and Merle, Philippe

Subjects
Computer Science - Software Engineering
Abstract

With the advent of cloud computing, different cloud providers with heterogeneous cloud services (compute, storage, network, applications, etc.) and their related Application Programming Interfaces (APIs) have emerged. This heterogeneity complicates the implementation of an interoperable cloud system. Several standards have been proposed to address this challenge and provide a unified interface to cloud resources. The Open Cloud Computing Interface (OCCI) thereby focuses on the standardization of a common API for Infrastructure-as-a-Service (IaaS) providers while the Topology and Orchestration Specification for Cloud Applications (TOSCA) focuses on the standardization of a template language to enable the proper definition of the topology of cloud applications and their orchestrations on top of a cloud system. TOSCA thereby does not define how the application topologies are created on the cloud. Therefore, we analyse the conceptual similarities between the two approaches and we study how we can integrate them to obtain a complete standard-based approach to manage both cloud infrastructure and cloud application layers. We propose an automated extensive mapping between the concepts of the two standards and we provide TOSCA Studio, a model-driven tool chain for TOSCA that conforms to OCCI. TOSCA Studio allows to graphically design cloud applications as well as to deploy and manage them at runtime using a fully model-driven cloud orchestrator based on the two standards. Our contribution is validated by successfully designing and deploying three cloud applications: WordPress, Node Cellar and Multi-Tier.

Published
2020

6. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Author

Strasser, Simone, Thompson, Alexander, Roohullah, Aflah, Sievert, William, Andelkovic, Vladimir, Knox, Jennifer, Davies, Janine, Asselah, Jamil, Brahmania, Mayur, Majeed, Habeeb, Villanueva, Luis, Yanez Weber, Patricio, Garrido, Marcelo, Pizarro, Gonzalo Ignacio, Yanez, Nicolas, Xu, Ruocai, Ou, Shuangyan, Ren, Zhenggang, Pan, Hongming, Meng, Zhiqiang, Gu, Kangsheng, Chen, Xi, Zhang, Tao, Hao, Chunyi, Cao, Peiguo, Guo, Yabing, Qin, Shukui, Xiao, Juxiang, Fang, Weijia, Wang, Xin, Bai, Yuxian, Chen, Xiaoming, Yan, Dong, Zhao, Hong, Ying, Jieer, Bonilla, Carlos, Urrego, Olga, Zambrano, Angela, Lema, Mauricio, Restrepo Gutierrez, Juan Carlos, Cardona, Andres, Franco Millan, Sandra, Oscar, Madiedo, Ramos, Victor, Merle, Philippe, LeSourd, Samuel, Edeline, Julien, Bronowicki, Jean-Pierre, Bourliere, Marc, Cattan, Stephane, Bouattour, Mohamed, Mineur, Laurent, Regnault, Helene, Dauvois, Barbara, Schulze, Kornelius, Folprecht, Gunnar, Geier, Andreas, Waidmann, Oliver, Finkelmeier, Fabian, Venerito, Marino, Berres, Marie-Luise, Berg, Thomas, Lange, Christian, Schmidt, Hartmut, Waldschmidt, Dirk T, Bitzer, Michael, McDermott, Ray, Duffy, Austin, Masi, Gianluca, Zagonel, Vittorina, Tonini, Giuseppe, Piscaglia, Fabio, Gori, Stefania, Rizzo, Mimma, Biscaldi, Elisa, Foltran, Luisa, Cabibbo, Giuseppe, Ikeda, Masafumi, Kudo, Masatoshi, Aikata, Hiroshi, Numata, Kazushi, Marusawa, Hiroyuki, Kato, Naoya, Kurosaki, Masayuki, Morimoto, Manabu, Yamashita, Tatsuya, Koga, Hironori, Masaki, Tsutomu, Tateishi, Ryosuke, Inaba, Yoshitaka, Arakawa, Tomohiro, Suzuki, Yoshiyuki, Akua, Norio, Kobayashi, Masahiro, Hosaka, Tetsuya, Nakamuta, Makoto, Oza, Noriko, Kondo, Shunsuke, Furuse, Junji, Nagashima, Fumio, Kitano, Masayuki, Takaguchi, Koichi, Ryoo, Baek-Yeol, Lim, Ho Yeong, Kim, Jee Hyun, Kim, Tae-You, Kim, Han Sang, Hernandez Hernandez, Carlos, Motola Kuba, Daniel, Segura Gonzalez, Manuel, Cabrera Luviano, Jesus, Huitzil Melendez, Fidel, Ramirez Godinez, Francisco, Silva-Bravo, Fernando, Gane, Edward, Stedman, Catherine, Kwiatkowski, Mariusz, Wyrwicz, Lucjan, Nowakowska-Zajdel, Ewa, Kraj, Leszek, Janczewska, Ewa, Surma-Wlodarczyk, Renata, Breder, Valeriy, Sekacheva, Marina, Orlova, Rashida, Vasilyev, Alexander, Zukov, Ruslan, Vladimirov, Vladimir, Minguez, Beatriz, Matilla Pena, Ana, Fernandez Castroagudin, Javier, Romero Gomez, Manuel, Luis Lledo, Jose, Rubin, Angel, Garcia Sanchez, Araceli, Calleja Panero, Jose, Yu, Ming-Chin, Shen, Ying-Chun, Huang, Yi-Hsiang, Jeng, Long-Bin, Chang, Ting-Tsung, Yang, Sheng-Shun, Chen, Shinn-Cherng, Dechaphunkul, Arunee, Tanwandee, Tawesak, Leerapun, Apinya, Seker, Mesut, Harputluoglu, Hakan, Cicin, Irfan, Oksuzoglu, Berna, Bilici, Mehmet, Sezgin Goksu, Sema, Artac, Mehmet, Cil, Timucin, Yalcin, Suayib, Meyer, Tim, Sarker, Debashis, Rao, Ankit, Palmer, Daniel, Evans, Jeff, Hubner, Richard, Finn, Richard, Ulahannan, Susanna, Zakari, Ahmed, Feun, Lynn, Al-Rajabi, Raed, Sung, Max, He, Aiwu, Kardosh, Adel, Goyal, Lipika, Li, Daneng, Choi, Minsig, Posada, Juan, Dodlapati, Jyothi, Shroff, Rachna, Agrawal, Saurabh, Gopaluni, Srivalli, Akce, Mehmet, Alese, Olatunji, Baron, Ari, Dunne, Richard, Loaiza-Bonilla, Arturo, Frenette, Catherine, Llovet, Josep M, Kumada, Hiromitsu, Cheng, Ann-Lii, Galle, Peter R, Kaneko, Shuichi, Wang, Anran, Mody, Kalgi, Dutcus, Corina, Dubrovsky, Leonid, Siegel, Abby B, and Finn, Richard S

Published
2023
Full Text
View/download PDF

7. Hypersensitivity infusion-associated reactions induced by enzyme replacement therapy in a cohort of patients with late-onset Pompe disease: An experience from the French Pompe Registry

Author

Lessard, Lola E.R., Tard, Céline, Salort-Campana, Emmanuelle, Sacconi, Sabrina, Béhin, Anthony, Bassez, Guillaume, Orlikowski, David, Merle, Philippe, Nollet, Sylvain, Gallay, Laure, Bérard, Frédéric, Robinson, Philip, Bouhour, Françoise, and Laforêt, Pascal

Published
2023
Full Text
View/download PDF

9. Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial

Author

Merle, Philippe, Blanc, Jean-Frédéric, Edeline, Julien, Le Malicot, Karine, Allaire, Manon, Assenat, Eric, Guarssifi, Meriem, Bouattour, Mohamed, Péron, Jean-Marie, Laurent-Puig, Pierre, Levrero, Massimo, Costentin, Charlotte, Guiu, Boris, Sokol, Harry, Tougeron, David, Aparicio, Thomas, Nault, Jean-Charles, and Phelip, Jean-Marc

Published
2023
Full Text
View/download PDF

10. TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial

Author

Féray, Cyrille, Campion, Loic, Mathurin, Philippe, Archambreaud, Isabelle, Mirabel, Xavier, Bronowicki, Jean Pierre, Rio, Emmanuel, Perret, Christophe, Mineur, Laurent, Oberti, Frédéric, Touchefeu, Yann, Gournay, Jérôme, Regnault, Hélène, Edeline, Julien, Rode, Agnès, Hillion, Patrick, Blanc, Jean Frédéric, Khac, Eric Nguyen, Azoulay, Daniel, Luciani, Alain, Preglisasco, Athena Galetto, Faurel-Paul, Elodie, Auble, Hélène, Mornex, Françoise, and Merle, Philippe

Published
2023
Full Text
View/download PDF

11. Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma

Author

Kelley, Robin Kate, Meyer, Tim, Rimassa, Lorenza, Merle, Philippe, Park, Joong-Won, Yau, Thomas, Chan, Stephen L, Blanc, Jean-Frederic, Tam, Vincent C, Tran, Albert, Dadduzio, Vincenzo, Markby, David W, Kaldate, Rajesh, Cheng, Ann-Lii, El-Khoueiry, Anthony B, and Abou-Alfa, Ghassan K

Subjects
Cancer, Clinical Trials and Supportive Activities, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Aged, Aged, 80 and over, Anilides, Carcinoma, Hepatocellular, Female, Humans, Liver Neoplasms, Male, Middle Aged, Neoplasm Staging, Placebos, Prognosis, Progression-Free Survival, Protein Kinase Inhibitors, Pyridines, Reference Values, Young Adult, alpha-Fetoproteins, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeThe phase III CELESTIAL study demonstrated improved overall survival (OS) and progression-free survival (PFS) with cabozantinib versus placebo in patients with previously treated, advanced hepatocellular carcinoma (HCC). We analyzed outcomes by baseline alpha-fetoprotein (AFP) and on-treatment AFP changes.Patients and methodsSerum AFP was measured every 8 weeks by blinded, centralized testing. Outcomes were analyzed by baseline AFP bifurcated at 400 ng/mL and by on-treatment AFP response (≥20% decrease from baseline at Week 8). The optimal cutoff for change in AFP at Week 8 was evaluated using maximally selected rank statistics.ResultsMedian OS for cabozantinib versus placebo was 13.9 versus 10.3 months [HR, 0.81; 95% confidence interval (CI), 0.62-1.04] for patients with baseline AFP

Published
2020

12. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial.

Author

Kelley, Robin Kate, Ryoo, Baek-Yeol, Merle, Philippe, Park, Joong-Won, Bolondi, Luigi, Chan, Stephen L, Lim, Ho Yeong, Baron, Ari D, Parnis, Francis, Knox, Jennifer, Cattan, Stéphane, Yau, Thomas, Lougheed, Julie C, Milwee, Steven, El-Khoueiry, Anthony B, Cheng, Ann-Lii, Meyer, Tim, and Abou-Alfa, Ghassan K

Subjects
Humans, Carcinoma, Hepatocellular, Liver Neoplasms, Anilides, Pyridines, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Adult, Aged, Aged, 80 and over, Middle Aged, Male, Young Adult, Sorafenib, cabozantinib, hepatocellular carcinoma, sorafenib, tyrosine kinase inhibitor, Clinical Research, Cancer, Clinical Trials and Supportive Activities, Digestive Diseases, Rare Diseases, Liver Cancer, Liver Disease, 6.1 Pharmaceuticals
Abstract

ObjectiveIn the phase 3 CELESTIAL trial, cabozantinib improved overall survival (OS) and progression-free survival (PFS) compared with placebo in patients with previously treated advanced hepatocellular carcinoma (HCC). This subgroup analysis evaluated cabozantinib in patients who had received sorafenib as the only prior systemic therapy.MethodsCELESTIAL randomised (2:1) patients with advanced HCC and Child-Pugh class A liver function to treatment with cabozantinib (60 mg daily) or placebo. Eligibility required prior treatment with sorafenib, and patients could have received ≤2 prior systemic regimens. The primary endpoint was OS. Outcomes in patients who had received sorafenib as the only prior therapy were analysed by duration of prior sorafenib (

Published
2020

15. OS-110 ARMCENVIN: multibipolar radiofrequency ablation of HCC using intratumourous versus extratumourous “no-touch” techniques. French multicentric randomized controlled trial (NCT 01008657)

Author

Seror, Olivier, primary, N'Kontchou, Gisele, additional, Rode, Agnès, additional, Merle, Philippe, additional, Aubé, Christophe, additional, Oberti, Frédéric, additional, Vilgrain, Valerie, additional, Bouattour, Mohamed, additional, Trillaud, Hervé, additional, Blanc, Jean-Frédéric, additional, Guiu, Boris, additional, Pageaux, Georges-Philippe, additional, Chevallier, Patrick, additional, Tran, Albert, additional, Portal, Jean-Jacques, additional, Nault, Jean Charles, additional, Sutter, Olivier, additional, Ganne-Carrié, Nathalie, additional, Nahon, Pierre, additional, and Vicaut, Eric, additional

Published
2024
Full Text
View/download PDF

16. THU-459-YI Long-term oncological results of percutaneous radiofrequency ablation for intrahepatic cholangiocarcinoma: a multicentric retrospective study

Author

Alitti, Clémentine, primary, Rode, Agnès, additional, Trillaud, Hervé, additional, Merle, Philippe, additional, Blanc, Jean-Frédéric, additional, Blaise, Lorraine, additional, Demory, Alix, additional, Gisèle, NKontchou, additional, Lemaire, Véronique Grando, additional, Ziol, Marianne, additional, Nahon, Pierre, additional, Ganne-Carrié, Nathalie, additional, Petit, Arthur, additional, Seror, Olivier, additional, Sutter, Olivier, additional, and Nault, Jean Charles, additional

Published
2024
Full Text
View/download PDF

17. THU-466 Treatment with Atezolizumab-Bevacizumab for hepatocellular carcinoma in the french population outside clinical trials: data from the prospective CHIEF cohort

Author

Allaire, Manon, primary, Hajer, Ben Khadhra, additional, Amaddeo, Giuliana, additional, Bouattour, Mohamed, additional, Brusset, Bleuenn, additional, Ziol, Marianne, additional, Merle, Philippe, additional, Blanc, Jean-Frédéric, additional, Uguen, Thomas, additional, Ganne-Carrié, Nathalie, additional, Cattan, Stéphane, additional, Riachi, Ghassan, additional, Loustaud-Ratti, Veronique, additional, Decaens, Thomas, additional, Silvain, Christine, additional, Peron, Jean Marie, additional, Baron, Aurore, additional, Pageaux, Georges-Philippe, additional, Oberti, Frédéric, additional, Anty, Rodolphe, additional, Manfredi, Sylvain, additional, Bourliere, Marc, additional, Ben Merabet, Yasmina, additional, Nousbaum, JeanB-aptiste, additional, Heurgue-Berlot, Alexandra, additional, Ollivier-Hourmand, Isabelle, additional, Ducournau, Gerard, additional, Ganry, Olivier, additional, Costentin, Charlotte, additional, and Khac, Eric Nguyen, additional

Published
2024
Full Text
View/download PDF

18. OS-060 Hepatocellular carcinoma development despite histological regression of liver fibrosis following HCV cure (ANRS CirVir, Hepather, LICAVIR)

Author

Nahon, Pierre, primary, lusivka-Nzinga, Clovis, additional, Merle, Philippe, additional, Zoulim, Fabien, additional, Decaens, Thomas, additional, Ganne-Carrié, Nathalie, additional, Pageaux, Georges-Philippe, additional, Leroy, Vincent, additional, Alric, Laurent, additional, Bronowicki, Jean-Pierre, additional, Bourliere, Marc, additional, Gournay, Jérôme, additional, Tran, Albert, additional, Pol, Stanislas, additional, Mathurin, Philippe, additional, Loustaud-Ratti, Veronique, additional, Metivier, Sophie, additional, de Lédinghen, Victor, additional, Abergel, Armand, additional, Thabut, Dominique, additional, Dalteroche, Louis, additional, Bouattour, Mohamed, additional, Asselah, Tarik, additional, Ouzan, Denis, additional, Cales, Paul, additional, Chazouillères, Olivier, additional, Gelu-Simeon, Moana, additional, Roulot, Dominique, additional, Boursier, Jerome, additional, Carole, Cagnot, additional, Tamazirt, Sonia, additional, Pascale, Alina, additional, Nilusmas, Samuel, additional, Lewin, Maite, additional, Ziol, Marianne, additional, Carrat, Fabrice, additional, and Duclos-Vallée, Jean-Charles, additional

Published
2024
Full Text
View/download PDF

20. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

Author

Kelley, Robin Kate, Rimassa, Lorenza, Cheng, Ann-Lii, Kaseb, Ahmed, Qin, Shukui, Zhu, Andrew X, Chan, Stephen L, Melkadze, Tamar, Sukeepaisarnjaroen, Wattana, Breder, Valery, Verset, Gontran, Gane, Edward, Borbath, Ivan, Rangel, Jose David Gomez, Ryoo, Baek-Yeol, Makharadze, Tamta, Merle, Philippe, Benzaghou, Fawzi, Banerjee, Kamalika, Hazra, Saswati, Fawcett, Jonathan, and Yau, Thomas

Published
2022
Full Text
View/download PDF

22. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Author

Yau, Thomas, Park, Joong-Won, Finn, Richard S, Cheng, Ann-Lii, Mathurin, Philippe, Edeline, Julien, Kudo, Masatoshi, Harding, James J, Merle, Philippe, Rosmorduc, Olivier, Wyrwicz, Lucjan, Schott, Eckart, Choo, Su Pin, Kelley, Robin Kate, Sieghart, Wolfgang, Assenat, Eric, Zaucha, Renata, Furuse, Junji, Abou-Alfa, Ghassan K, El-Khoueiry, Anthony B, Melero, Ignacio, Begic, Damir, Chen, Gong, Neely, Jaclyn, Wisniewski, Tami, Tschaika, Marina, and Sangro, Bruno

Published
2022
Full Text
View/download PDF

25. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

Author

Abou-Alfa, Ghassan K, Meyer, Tim, Cheng, Ann-Lii, El-Khoueiry, Anthony B, Rimassa, Lorenza, Ryoo, Baek-Yeol, Cicin, Irfan, Merle, Philippe, Chen, YenHsun, Park, Joong-Won, Blanc, Jean-Frederic, Bolondi, Luigi, Klümpen, Heinz-Josef, Chan, Stephen L, Zagonel, Vittorina, Pressiani, Tiziana, Ryu, Min-Hee, Venook, Alan P, Hessel, Colin, Borgman-Hagey, Anne E, Schwab, Gisela, and Kelley, Robin K

Subjects
Digestive Diseases, Rare Diseases, Clinical Trials and Supportive Activities, Clinical Research, Liver Disease, Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Anilides, Antineoplastic Agents, Carcinoma, Hepatocellular, Disease-Free Survival, Double-Blind Method, Female, Humans, Kaplan-Meier Estimate, Liver Neoplasms, Male, Middle Aged, Pyridines, Receptor Protein-Tyrosine Kinases, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundCabozantinib inhibits tyrosine kinases, including vascular endothelial growth factor receptors 1, 2, and 3, MET, and AXL, which are implicated in the progression of hepatocellular carcinoma and the development of resistance to sorafenib, the standard initial treatment for advanced disease. This randomized, double-blind, phase 3 trial evaluated cabozantinib as compared with placebo in previously treated patients with advanced hepatocellular carcinoma.MethodsA total of 707 patients were randomly assigned in a 2:1 ratio to receive cabozantinib (60 mg once daily) or matching placebo. Eligible patients had received previous treatment with sorafenib, had disease progression after at least one systemic treatment for hepatocellular carcinoma, and may have received up to two previous systemic regimens for advanced hepatocellular carcinoma. The primary end point was overall survival. Secondary end points were progression-free survival and the objective response rate.ResultsAt the second planned interim analysis, the trial showed significantly longer overall survival with cabozantinib than with placebo. Median overall survival was 10.2 months with cabozantinib and 8.0 months with placebo (hazard ratio for death, 0.76; 95% confidence interval [CI], 0.63 to 0.92; P=0.005). Median progression-free survival was 5.2 months with cabozantinib and 1.9 months with placebo (hazard ratio for disease progression or death, 0.44; 95% CI, 0.36 to 0.52; P

Published
2018

26. Analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) and Child–Pugh (CP)-B liver function treated with regorafenib in routine clinical practice in the observational REFINE study.

Author

Kim, Yoon Jun, primary, Merle, Philippe, additional, Finn, Richard S., additional, Kudo, Masatoshi, additional, Klümpen, Heinz-Josef, additional, Lim, Ho Yeong, additional, Pinter, Matthias, additional, Babajanyan, Svetlana, additional, Khan, Javeed, additional, Awan, Maria, additional, Özgürdal, Kirhan, additional, and Qin, Shukui, additional

Published
2024
Full Text
View/download PDF

27. Lenvatinib plus pembrolizumab versus lenvatinib alone as first-line therapy for advanced hepatocellular carcinoma: Longer-term efficacy and safety results from the phase 3 LEAP-002 study.

Author

Finn, Richard S., primary, Kudo, Masatoshi, additional, Merle, Philippe, additional, Meyer, Tim, additional, Qin, Shukui, additional, Ikeda, Masafumi, additional, Xu, Ruocai, additional, Edeline, Julien, additional, Ryoo, Baek-Yeol, additional, Ren, Zhenggang, additional, Cheng, Ann-Lii, additional, Galle, Peter R., additional, Kaneko, Shuichi, additional, Kumada, Hiromitsu, additional, Wang, Anran, additional, Mody, Kalgi, additional, Dubrovsky, Leonid, additional, Siegel, Abby B., additional, and Llovet, Josep M, additional

Published
2024
Full Text
View/download PDF

28. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial

Author

Galle, Peter R, Finn, Richard S, Qin, Shukui, Ikeda, Masafumi, Zhu, Andrew X, Kim, Tae-You, Kudo, Masatoshi, Breder, Valeriy, Merle, Philippe, Kaseb, Ahmed, Li, Daneng, Mulla, Sohail, Verret, Wendy, Xu, Derek-Zhen, Hernandez, Sairy, Ding, Beiying, Liu, Juan, Huang, Chen, Lim, Ho Yeong, Cheng, Ann-Lii, and Ducreux, Michel

Published
2021
Full Text
View/download PDF

29. Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma

Author

Assenat, Eric, Delhom-Christol, Elisabeth, Guiu, Boris, Ilonca, Alina D., Lonjon, Julie, Pageaux, Georges-Philippe, Abdel-Rehim, Mohamed, Al-laham, Wassim, Bouattour, Mohamed, Castera, Laurent, Dieudonné, Arnaud, Lebtahi, Rachida, Ronot, Maxime, Sibert, Annie, Vilgrain, Valérie, Barraud, Hélène, Bazin, Christophe, Bronowicki, Jean-Pierre, Laurent, Valérie, Mathias, Elodie, Chagneau-Derrode, Carine, Perdrisot, Rémy, Silvain, Christine, Tasu, Jean-Pierre, RenéGerolami, Patrick Borentain, Mundler, Olivier, Seitz, Jean-Francois, Vidal, Vincent, Aubé, Christophe, Bouvier, Antoine, Couturier, Olivier, Oberti, Frédéric, Vervueren, Laurent, Brenot-Rossi, Isabelle, Raoul, Jean-Luc, Sar-ran, Anthony, Chalaye, Julia, Costentin, Charlotte, Itti, Emmanuel, Kobeiter, Hicham, Luciani, Alain, Adam, René, Lewin, Maïté, Samuel, Didier, Edeline, Julien, Garin, Etienne, Rolland, Yan, Archambeaud, Isabelle, Eugene, Thomas, Frampas, Eric, Cassinotto, Christophe, Guyot, Martine, Hiriart, Jean-Baptiste, Lapuyade, Bruno, Vergniol, Julien, Bachellier, Philippe, Detour, Julien, Duclos, Bernard, Greget, Michel, Habersetzer, Francois, Imperiale, Alessio, Merle, Philippe, Rode, Agnès, Morvan, Julie, Nguyen-Khac, Eric, Yzet, Thierry, Baudin, Guillaume, Chevallier, Patrick, Mahamat, Abakar, Piche, Thierry, Razzouk, Micheline, Hillon, Patrick, Loffroy, Romaric, Toubeau, Michel, Vincent, Julie, Barabino, Gabriele, Bouarioua, Nadia, Cuilleron, Muriel, Ecochard, Marie, Prevot-Bitot, Nathalie, Leroy, Vincent, Roux, Julie, Sengel, Christian, Bourcier, Valérie, Carrie, Nathalie Ganne, Seror, Olivier, Costo, Sylvie, Dao, Thông, Pelage, Jean-Pierre, Dumortier, Jérôme, Giammarile, Francesco, Valette, Pierre-Jean, Ghazzar, Nadia, Pellerin, Olivier, Taieb, Julien, Weinmann, Pierre, Berlot, Alexandra Heurgue, Marcus, Claude, Sommacale, Daniele, Castilla-Lièvre, Maria-Angéla, Maitre, Sophie, Marthey, Lysiane, Zarca, Kevin, Mimouni, Maroua, Pereira, Helena, Chatellier, Gilles, and Durand-Zaleski, Isabelle

Published
2021
Full Text
View/download PDF

31. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

Author

Muñoz-Martínez, Sergio, Sapena, Victor, Forner, Alejandro, Nault, Jean-Charles, Sapisochin, Gonzalo, Rimassa, Lorenza, Sangro, Bruno, Bruix, Jordi, Sanduzzi-Zamparelli, Marco, Hołówko, Wacław, El Kassas, Mohamed, Mocan, Tudor, Bouattour, Mohamed, Merle, Philippe, Hoogwater, Frederik J.H., Alqahtani, Saleh A., Reeves, Helen L., Pinato, David J., Giorgakis, Emmanouil, Meyer, Tim, Villadsen, Gerda Elisabeth, Wege, Henning, Salati, Massimiliano, Mínguez, Beatriz, Di Costanzo, Giovan Giuseppe, Roderburg, Christoph, Tacke, Frank, Varela, María, Galle, Peter R., Alvares-da-Silva, Mario Reis, Trojan, Jörg, Bridgewater, John, Cabibbo, Giuseppe, Toso, Christian, Lachenmayer, Anja, Casadei-Gardini, Andrea, Toyoda, Hidenori, Lüdde, Tom, Villani, Rosanna, Matilla Peña, Ana María, Guedes Leal, Cassia Regina, Ronzoni, Monica, Delgado, Manuel, Perelló, Christie, Pascual, Sonia, Lledó, José Luis, Argemi, Josepmaria, Basu, Bristi, da Fonseca, Leonardo, Acevedo, Juan, Siebenhüner, Alexander R., Braconi, Chiara, Meyers, Brandon M., Granito, Alessandro, Sala, Margarita, Rodríguez-Lope, Carlos, Blaise, Lorraine, Romero-Gómez, Manuel, Piñero, Federico, Gomez, Dhanny, Mello, Vivianne, Pinheiro Alves, Rogerio Camargo, França, Alex, Branco, Fernanda, Brandi, Giovanni, Pereira, Gustavo, Coll, Susanna, Guarino, Maria, Benítez, Carlos, Anders, Maria Margarita, Bandi, Juan C., Vergara, Mercedes, Calvo, Mariona, Peck-Radosavljevic, Markus, García-Juárez, Ignacio, Cardinale, Vincenzo, Lozano, Mar, Gambato, Martina, Okolicsanyi, Stefano, Morales-Arraez, Dalia, Elvevi, Alessandra, Muñoz, Alberto E., Lué, Alberto, Iavarone, Massimo, and Reig, Maria

Published
2021
Full Text
View/download PDF

32. Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2

Author

Kudo, Masatoshi, Galle, Peter R., Brandi, Giovanni, Kang, Yoon-Koo, Yen, Chia-Jui, Finn, Richard S., Llovet, Josep M., Assenat, Eric, Merle, Philippe, Chan, Stephen L., Palmer, Daniel H., Ikeda, Masafumi, Yamashita, Tatsuya, Vogel, Arndt, Huang, Yi-Hsiang, Abada, Paolo B., Yoshikawa, Reigetsu, Shinozaki, Kenta, Wang, Chunxiao, Widau, Ryan C., and Zhu, Andrew X.

Published
2021
Full Text
View/download PDF

34. Long‐term oncological results of percutaneous radiofrequency ablation for intrahepatic cholangiocarcinoma.

Author

Alitti, Clémentine, Rode, Agnès, Trillaud, Hervé, Merle, Philippe, Blanc, Jean‐Frédéric, Blaise, Lorraine, Demory, Alix, Nkontchou, Gisele, Grando, Véronique, Ziol, Marianne, Nahon, Pierre, Ganne‐Carrié, Nathalie, Petit, Arthur, Seror, Olivier, Sutter, Olivier, and Nault, Jean‐Charles

Subjects
CATHETER ablation, CHOLANGIOCARCINOMA, OVERALL survival, ADJUVANT chemotherapy, CANCER relapse
Abstract

Introduction: The effectiveness of percutaneous radiofrequency ablation (RFA) in intrahepatic cholangiocarcinomas (iCCA) remains insufficiently studied. Methods: We conducted a retrospective study including patients with histologically proven iCCA within Milan criteria treated by percutaneous RFA from 2000 to 2022. The primary outcome was overall survival in treatment‐naive patients and secondary outcomes included ablation completeness, adverse events, local and distant recurrence. A total of 494 patients with hepatocellular carcinoma (HCC) on cirrhosis treated by RFA were included as a comparison group. Oncological events were analysed using Kaplan–Meier, log‐rank and univariate/multivariate Cox models. Results: The main population included 71 patients, mostly cirrhotic (80%) with solitary tumours (66%) of a median size of 24 mm. Local recurrence was 45% at 5 years, lower in multibipolar versus monopolar RFA (22% vs. 55%, p =.007). In treatment‐naive patients (n = 45), median overall and recurrence‐free survivals were 26 and 11 months, respectively. Tumour size (p =.01) and Child‐Pugh B (p =.001) were associated with death. The rate of distant recurrence was 59% at 5 years significantly lower for single tumours of less than 2 (p =.002) or 3 cm (p =.02). In cirrhotic patients naïve of previous treatment (n = 40), overall survival was shorter than in HCC (26 vs 68 months, p <.0001), with more local recurrences (p <.0001). Among distant recurrences, 50% were extrahepatic metastases compared to 12% in HCC (p <.001). Conclusion: Multibipolar RFA provides better results in terms of tumour recurrence than monopolar RFA and could be used to treat small iCCA (<3 cm). Adjuvant chemotherapy should be discussed due to the frequent extra‐hepatic metastasis at recurrence. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Electrophysiological features of chronic inflammatory demyelinating polyradiculoneuropathy associated with IgG4 antibodies targeting neurofascin 155 or contactin 1 glycoproteins

Author

Kouton, Ludivine, Boucraut, José, Devaux, Jérome, Rajabally, Yusuf A., Adams, David, Antoine, Jean Christophe, Bourdain, Frédéric, Brodovitch, Alexandre, Camdessanché, Jean-Philippe, Cauquil, Cécile, Ciron, Jonathan, Dubard, Thierry, Echaniz-Laguna, Andoni, Grapperon, Aude-Marie, Juntas-Morales, Raul, Kremer, Laurent, Kuntzer, Thierry, Labeyrie, Céline, Lanfranco, Luca, Léger, Jean-Marc, Maisonobe, Thierry, Mavroudakis, Nicolas, Mecharles-Darrigol, Sylvie, Merle, Philippe, Noury, Jean-Baptiste, Rouaud, Violaine, Tard, Céline, Théaudin, Marie, Vallat, Jean-Michel, Viala, Karine, Attarian, Shahram, and Delmont, Emilien

Published
2020
Full Text
View/download PDF

36. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Author

Llovet, Josep M, primary, Kudo, Masatoshi, additional, Merle, Philippe, additional, Meyer, Tim, additional, Qin, Shukui, additional, Ikeda, Masafumi, additional, Xu, Ruocai, additional, Edeline, Julien, additional, Ryoo, Baek-Yeol, additional, Ren, Zhenggang, additional, Masi, Gianluca, additional, Kwiatkowski, Mariusz, additional, Lim, Ho Yeong, additional, Kim, Jee Hyun, additional, Breder, Valeriy, additional, Kumada, Hiromitsu, additional, Cheng, Ann-Lii, additional, Galle, Peter R, additional, Kaneko, Shuichi, additional, Wang, Anran, additional, Mody, Kalgi, additional, Dutcus, Corina, additional, Dubrovsky, Leonid, additional, Siegel, Abby B, additional, Finn, Richard S, additional, Strasser, Simone, additional, Thompson, Alexander, additional, Roohullah, Aflah, additional, Sievert, William, additional, Andelkovic, Vladimir, additional, Knox, Jennifer, additional, Davies, Janine, additional, Asselah, Jamil, additional, Brahmania, Mayur, additional, Majeed, Habeeb, additional, Villanueva, Luis, additional, Yanez Weber, Patricio, additional, Garrido, Marcelo, additional, Pizarro, Gonzalo Ignacio, additional, Yanez, Nicolas, additional, Ou, Shuangyan, additional, Pan, Hongming, additional, Meng, Zhiqiang, additional, Gu, Kangsheng, additional, Chen, Xi, additional, Zhang, Tao, additional, Hao, Chunyi, additional, Cao, Peiguo, additional, Guo, Yabing, additional, Xiao, Juxiang, additional, Fang, Weijia, additional, Wang, Xin, additional, Bai, Yuxian, additional, Chen, Xiaoming, additional, Yan, Dong, additional, Zhao, Hong, additional, Ying, Jieer, additional, Bonilla, Carlos, additional, Urrego, Olga, additional, Zambrano, Angela, additional, Lema, Mauricio, additional, Restrepo Gutierrez, Juan Carlos, additional, Cardona, Andres, additional, Franco Millan, Sandra, additional, Oscar, Madiedo, additional, Ramos, Victor, additional, LeSourd, Samuel, additional, Bronowicki, Jean-Pierre, additional, Bourliere, Marc, additional, Cattan, Stephane, additional, Bouattour, Mohamed, additional, Mineur, Laurent, additional, Regnault, Helene, additional, Dauvois, Barbara, additional, Schulze, Kornelius, additional, Folprecht, Gunnar, additional, Geier, Andreas, additional, Waidmann, Oliver, additional, Finkelmeier, Fabian, additional, Venerito, Marino, additional, Berres, Marie-Luise, additional, Berg, Thomas, additional, Lange, Christian, additional, Schmidt, Hartmut, additional, Waldschmidt, Dirk T, additional, Bitzer, Michael, additional, McDermott, Ray, additional, Duffy, Austin, additional, Zagonel, Vittorina, additional, Tonini, Giuseppe, additional, Piscaglia, Fabio, additional, Gori, Stefania, additional, Rizzo, Mimma, additional, Biscaldi, Elisa, additional, Foltran, Luisa, additional, Cabibbo, Giuseppe, additional, Aikata, Hiroshi, additional, Numata, Kazushi, additional, Marusawa, Hiroyuki, additional, Kato, Naoya, additional, Kurosaki, Masayuki, additional, Morimoto, Manabu, additional, Yamashita, Tatsuya, additional, Koga, Hironori, additional, Masaki, Tsutomu, additional, Tateishi, Ryosuke, additional, Inaba, Yoshitaka, additional, Arakawa, Tomohiro, additional, Suzuki, Yoshiyuki, additional, Akua, Norio, additional, Kobayashi, Masahiro, additional, Hosaka, Tetsuya, additional, Nakamuta, Makoto, additional, Oza, Noriko, additional, Kondo, Shunsuke, additional, Furuse, Junji, additional, Nagashima, Fumio, additional, Kitano, Masayuki, additional, Takaguchi, Koichi, additional, Kim, Tae-You, additional, Kim, Han Sang, additional, Hernandez Hernandez, Carlos, additional, Motola Kuba, Daniel, additional, Segura Gonzalez, Manuel, additional, Cabrera Luviano, Jesus, additional, Huitzil Melendez, Fidel, additional, Ramirez Godinez, Francisco, additional, Silva-Bravo, Fernando, additional, Gane, Edward, additional, Stedman, Catherine, additional, Wyrwicz, Lucjan, additional, Nowakowska-Zajdel, Ewa, additional, Kraj, Leszek, additional, Janczewska, Ewa, additional, Surma-Wlodarczyk, Renata, additional, Sekacheva, Marina, additional, Orlova, Rashida, additional, Vasilyev, Alexander, additional, Zukov, Ruslan, additional, Vladimirov, Vladimir, additional, Minguez, Beatriz, additional, Matilla Pena, Ana, additional, Fernandez Castroagudin, Javier, additional, Romero Gomez, Manuel, additional, Luis Lledo, Jose, additional, Rubin, Angel, additional, Garcia Sanchez, Araceli, additional, Calleja Panero, Jose, additional, Yu, Ming-Chin, additional, Shen, Ying-Chun, additional, Huang, Yi-Hsiang, additional, Jeng, Long-Bin, additional, Chang, Ting-Tsung, additional, Yang, Sheng-Shun, additional, Chen, Shinn-Cherng, additional, Dechaphunkul, Arunee, additional, Tanwandee, Tawesak, additional, Leerapun, Apinya, additional, Seker, Mesut, additional, Harputluoglu, Hakan, additional, Cicin, Irfan, additional, Oksuzoglu, Berna, additional, Bilici, Mehmet, additional, Sezgin Goksu, Sema, additional, Artac, Mehmet, additional, Cil, Timucin, additional, Yalcin, Suayib, additional, Sarker, Debashis, additional, Rao, Ankit, additional, Palmer, Daniel, additional, Evans, Jeff, additional, Hubner, Richard, additional, Finn, Richard, additional, Ulahannan, Susanna, additional, Zakari, Ahmed, additional, Feun, Lynn, additional, Al-Rajabi, Raed, additional, Sung, Max, additional, He, Aiwu, additional, Kardosh, Adel, additional, Goyal, Lipika, additional, Li, Daneng, additional, Choi, Minsig, additional, Posada, Juan, additional, Dodlapati, Jyothi, additional, Shroff, Rachna, additional, Agrawal, Saurabh, additional, Gopaluni, Srivalli, additional, Akce, Mehmet, additional, Alese, Olatunji, additional, Baron, Ari, additional, Dunne, Richard, additional, Loaiza-Bonilla, Arturo, additional, and Frenette, Catherine, additional

Published
2023
Full Text
View/download PDF

38. soCloud: A service-oriented component-based PaaS for managing portability, provisioning, elasticity, and high availability across multiple clouds

Author

Paraiso, Fawaz, Merle, Philippe, and Seinturier, Lionel

Subjects
Computer Science - Software Engineering, Computer Science - Distributed, Parallel, and Cluster Computing
Abstract

Multi-cloud computing is a promising paradigm to support very large scale world wide distributed applications. Multi-cloud computing is the usage of multiple, independent cloud environments, which assumed no priori agreement between cloud providers or third party. However, multi-cloud computing has to face several key challenges such as portability, provisioning, elasticity, and high availability. Developers will not only have to deploy applications to a specific cloud, but will also have to consider application portability from one cloud to another, and to deploy distributed applications spanning multiple clouds. This article presents soCloud a service-oriented component-based Platform as a Service (PaaS) for managing portability, elasticity, provisioning, and high availability across multiple clouds. soCloud is based on the OASIS Service Component Architecture (SCA) standard in order to address portability. soCloud provides services for managing provisioning, elasticity, and high availability across multiple clouds. soCloud has been deployed and evaluated on top of ten existing cloud providers: Windows Azure, DELL KACE, Amazon EC2, CloudBees, OpenShift, dotCloud, Jelastic, Heroku, Appfog, and an Eucalyptus private cloud.

Published
2014
Full Text
View/download PDF

39. Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis

Author

Bonnin, Marc, Fares, Nadim, Testoni, Barbara, Estornes, Yann, Weber, Kathrin, Vanbervliet, Béatrice, Lefrançois, Lydie, Garcia, Amandine, Kfoury, Alain, Pez, Floriane, Coste, Isabelle, Saintigny, Pierre, Viari, Alain, Lang, Kévin, Guey, Baptiste, Hervieu, Valérie, Bancel, Brigitte, Bartoch, Birke, Durantel, David, Renno, Toufic, Merle, Philippe, and Lebecque, Serge

Published
2019
Full Text
View/download PDF

40. A Lexical and Semantical Analysis on REST Cloud Computing APIs

Author

Petrillo, Fabio, Merle, Philippe, Palma, Francis, Moha, Naouel, Guéhéneuc, Yann-Gaël, Barbosa, Simone Diniz Junqueira, Series Editor, Filipe, Joaquim, Series Editor, Kotenko, Igor, Series Editor, Sivalingam, Krishna M., Series Editor, Washio, Takashi, Series Editor, Yuan, Junsong, Series Editor, Zhou, Lizhu, Series Editor, Ferguson, Donald, editor, Muñoz, Víctor Méndez, editor, Cardoso, Jorge, editor, Helfert, Markus, editor, and Pahl, Claus, editor

Published
2018
Full Text
View/download PDF

41. Tumour-specific amplitude-modulated radiofrequency electromagnetic fields induce differentiation of hepatocellular carcinoma via targeting Cav3.2 T-type voltage-gated calcium channels and Ca2+ influx

Author

Jimenez, Hugo, Wang, Minghui, Zimmerman, Jacquelyn W., Pennison, Michael J., Sharma, Sambad, Surratt, Trevor, Xu, Zhi-Xiang, Brezovich, Ivan, Absher, Devin, Myers, Richard M., DeYoung, Barry, Caudell, David L., Chen, Dongquan, Lo, Hui-Wen, Lin, Hui-Kuan, Godwin, Dwayne W., Olivier, Michael, Ghanekar, Anand, Chen, Kui, Miller, Lance D., Gong, Yijian, Capstick, Myles, D'Agostino, Ralph B., Jr, Munden, Reginald, Merle, Philippe, Barbault, Alexandre, Blackstock, Arthur W., Bonkovsky, Herbert L., Yang, Guang-Yu, Jin, Guangxu, Liu, Liang, Zhang, Wei, Watabe, Kounosuke, Blackman, Carl F., and Pasche, Boris C.

Published
2019
Full Text
View/download PDF

42. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

Author

Moussata, Driffa, Grangé, Jean-Didier, Ratziu, Vlad, Khemissa-Akouz, Faiza, Regnault, Hélène, Dauvois, Barbara, Zarski, Jean-Pierre, Ollivier-Hourmand, Isabelle, Manfredi, Sylvain, Debette-Gratien, Marilyne, Gangloff, Alice, Fontanges, Thierry, Baron, Aurore, Bouattour, Mohamed, Vincent, Julie, Sieghart, Wolfgang, Maieron, Andreas, Peeters, Marc, Delwaide, Jean, Lasser, Luc, Berg, Thomas, Schultheiß, Michael, Zipprich, Alexander, Trojan, Joerg, Ehmer, Ursula, Luppi, Gabriele, Luca, Giovanni, Tamberi, Stefano, Amoroso, Domenico, Alabiso, Oscar, Buonadonna, Angela, Toniutto, Pierluigi, Tamburini, Emiliano, Cubillo, Antonio, Muñoz, Andrés, Guillén, Carmen, Sánchez, Gloria, Manzano, Hermini, Navarro, Victor, Ales, Inmaculada, Massuti, Bartomeu, Dank, Magdolna, Bodoky, György, Kahan, Zsuzsanna, Horváth, Zsolt, Gabrail, Nashat, Ozer, Howard, Galanopoulos, Christos, Hauke, Ralph, Raj, Moses, Harputluoglu, Hakan, Sevinc, Alper, Goker, Erdem, Coker, Ahmet, Yalcin, Suayib, Ali, Muhammet, Ata, Ozlem, Tugba, Ilkay, El Kassas, Mohammed, Abdel, Amr, Wakid, Imam, Shamaa, Sameh, El Lahlouby, Nasr, Kohail, Hanaa, Makarem, Jawad, Chehade, Issam, Farhat, Fadi, López, Carlos, Marín, Miguel, Merle, Philippe, Blanc, Jean-Frederic, Phelip, Jean-Marc, Pelletier, Gilles, Bronowicki, Jean-Pierre, Touchefeu, Yann, Pageaux, Georges, Gerolami, René, Habersetzer, François, Nguyen-Khac, Eric, Casadei-Gardini, Andrea, Borbath, Ivan, Tran, Albert, Wege, Henning, Saad, Amr Shafik, Colombo, Massimo, Abergel, Armand, Richou, Carine, Waked, Imam, Yee, Nelson S, Molé, Audrey, Attali, Pierre, Le Boulicaut, Julie, and Vasseur, Bérangère

Published
2019
Full Text
View/download PDF

45. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Zhu, Andrew X, Kang, Yoon-Koo, Yen, Chia-Jui, Finn, Richard S, Galle, Peter R, Llovet, Josep M, Assenat, Eric, Brandi, Giovanni, Pracht, Marc, Lim, Ho Yeong, Rau, Kun-Ming, Motomura, Kenta, Ohno, Izumi, Merle, Philippe, Daniele, Bruno, Shin, Dong Bok, Gerken, Guido, Borg, Christophe, Hiriart, Jean-Baptiste, Okusaka, Takuji, Morimoto, Manabu, Hsu, Yanzhi, Abada, Paolo B, and Kudo, Masatoshi

Published
2019
Full Text
View/download PDF

46. Towards Exogenous Coordination of Concurrent Cloud Applications.

Author

Le-Khanh, Trinh, Nguyen, Hoang-Gia, Bliudze, Simon, and Merle, Philippe

Subjects
CLOUD computing, MODULAR design
Abstract

Cloud computing offers opportunities to increase productivity and reduce costs. Quickly adapting to changing needs is key to maintaining cloud applications. In traditional development, coordination is implemented in computational code. Although change impact analyses are studied, adjusting the implementation is time-consuming and error-prone when the coordination strategy changes. Exogenous coordination separates the implemented coordination and computational code to cope with this problem. This separation improves the reusability of components. Additionally, other applications with similar interaction patterns can reuse the coordination specification. The main contribution of this paper is to propose a methodology to develop and maintain cloud applications following the exogenous approach. To illustrate the idea, we introduce a new framework named OCCIwareBIP, which integrates JavaBIP — a framework for the exogenous coordination of concurrent Java components into OCCIware — a framework for designing cloud applications. We also leverage the coordination model to verify the deadlock-freedom of the cloud application. Finally, we present an application to show the ability of our approach to guarantee the safety and benefits of modularization in developing concurrent cloud applications. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. Collaborative validation of the quantification method for 57 allergens in ready to inject fragrance samples

Author

Pérès, Christophe, primary, Corbi, Elise, additional, David, Nathalie, additional, Masson, Jérôme, additional, Cicchetti, Esmeralda, additional, Kupfermann, Nikolai, additional, Kuropka, Gryta, additional, Tacnet, Nicolas, additional, Roach, Nick, additional, Delacôte, Anne‐Marie, additional, Gervais, Gaël, additional, Schippa, Christine, additional, Ventura, Merixtell, additional, and Merle, Philippe, additional

Published
2023
Full Text
View/download PDF

49. A Generic Deployment Framework for Grid Computing and Distributed Applications

Author

Flissi, Areski and Merle, Philippe

Subjects
Computer Science - Distributed, Parallel, and Cluster Computing
Abstract

Deployment of distributed applications on large systems, and especially on grid infrastructures, becomes a more and more complex task. Grid users spend a lot of time to prepare, install and configure middleware and application binaries on nodes, and eventually start their applications. The problem is that the deployment process is composed of many heterogeneous tasks that have to be orchestrated in a specific correct order. As a consequence, the automatization of the deployment process is currently very difficult to reach. To address this problem, we propose in this paper a generic deployment framework allowing to automatize the execution of heterogeneous tasks composing the whole deployment process. Our approach is based on a reification as software components of all required deployment mechanisms or existing tools. Grid users only have to describe the configuration to deploy in a simple natural language instead of programming or scripting how the deployment process is executed. As a toy example, this framework is used to deploy CORBA component-based applications and OpenCCM middleware on one thousand nodes of the French Grid5000 infrastructure., Comment: The original publication is available at http://www.springerlink.com

Published
2007
Full Text
View/download PDF

50. A Model-Driven Tool Chain for OCCI

Author

Zalila, Faiez, Challita, Stéphanie, Merle, Philippe, Hutchison, David, Series editor, Kanade, Takeo, Series editor, Kittler, Josef, Series editor, Kleinberg, Jon M., Series editor, Mattern, Friedemann, Series editor, Mitchell, John C., Series editor, Naor, Moni, Series editor, Pandu Rangan, C., Series editor, Steffen, Bernhard, Series editor, Terzopoulos, Demetri, Series editor, Tygar, Doug, Series editor, Weikum, Gerhard, Series editor, Panetto, Hervé, editor, Debruyne, Christophe, editor, Gaaloul, Walid, editor, Papazoglou, Mike, editor, Paschke, Adrian, editor, Ardagna, Claudio Agostino, editor, and Meersman, Robert, editor

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results